354 related articles for article (PubMed ID: 15967266)
1. Virus specific immune responses after human neoadjuvant adenovirus-mediated suicide gene therapy for prostate cancer.
van der Linden RR; Haagmans BL; Mongiat-Artus P; van Doornum GJ; Kraaij R; Kadmon D; Aguilar-Cordova E; Osterhaus AD; van der Kwast TH; Bangma CH
Eur Urol; 2005 Jul; 48(1):153-61. PubMed ID: 15967266
[TBL] [Abstract][Full Text] [Related]
2. Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients.
Satoh T; Teh BS; Timme TL; Mai WY; Gdor Y; Kusaka N; Fujita T; Pramudji CK; Vlachaki MT; Ayala G; Wheeler T; Amato R; Miles BJ; Kadmon D; Butler EB; Thompson TC
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):562-71. PubMed ID: 15145177
[TBL] [Abstract][Full Text] [Related]
3. Phase I and biodistribution study of recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene and ganciclovir administration in patients with head and neck cancer and other malignant tumors.
Xu F; Li S; Li XL; Guo Y; Zou BY; Xu R; Liao H; Zhao HY; Zhang Y; Guan ZZ; Zhang L
Cancer Gene Ther; 2009 Sep; 16(9):723-30. PubMed ID: 19363470
[TBL] [Abstract][Full Text] [Related]
4. Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer.
Ayala G; Satoh T; Li R; Shalev M; Gdor Y; Aguilar-Cordova E; Frolov A; Wheeler TM; Miles BJ; Rauen K; Teh BS; Butler EB; Thompson TC; Kadmon D
Mol Ther; 2006 Apr; 13(4):716-28. PubMed ID: 16480930
[TBL] [Abstract][Full Text] [Related]
5. Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer.
Shalev M; Kadmon D; Teh BS; Butler EB; Aguilar-Cordova E; Thompson TC; Herman JR; Adler HL; Scardino PT; Miles BJ
J Urol; 2000 Jun; 163(6):1747-50. PubMed ID: 10799174
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer.
Freytag SO; Khil M; Stricker H; Peabody J; Menon M; DePeralta-Venturina M; Nafziger D; Pegg J; Paielli D; Brown S; Barton K; Lu M; Aguilar-Cordova E; Kim JH
Cancer Res; 2002 Sep; 62(17):4968-76. PubMed ID: 12208748
[TBL] [Abstract][Full Text] [Related]
7. A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer.
Hall SJ; Canfield SE; Yan Y; Hassen W; Selleck WA; Chen SH
Gene Ther; 2002 Apr; 9(8):511-7. PubMed ID: 11948376
[TBL] [Abstract][Full Text] [Related]
8. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy.
Sterman DH; Recio A; Vachani A; Sun J; Cheung L; DeLong P; Amin KM; Litzky LA; Wilson JM; Kaiser LR; Albelda SM
Clin Cancer Res; 2005 Oct; 11(20):7444-53. PubMed ID: 16243818
[TBL] [Abstract][Full Text] [Related]
10. Local inflammatory response and vector spread after direct intraprostatic injection of a recombinant adenovirus containing the herpes simplex virus thymidine kinase gene and ganciclovir therapy in mice.
Timme TL; Hall SJ; Barrios R; Woo SL; Aguilar-Cordova E; Thompson TC
Cancer Gene Ther; 1998; 5(2):74-82. PubMed ID: 9570298
[TBL] [Abstract][Full Text] [Related]
11. Adenovirus-mediated herpes simplex virus thymidine kinase gene therapy in BT4C rat glioma model.
Tyynelä K; Sandmair AM; Turunen M; Vanninen R; Vainio P; Kauppinen R; Johansson R; Vapalahti M; Ylä-Herttuala S
Cancer Gene Ther; 2002 Nov; 9(11):917-24. PubMed ID: 12386830
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse.
Paielli DL; Wing MS; Rogulski KR; Gilbert JD; Kolozsvary A; Kim JH; Hughes J; Schnell M; Thompson T; Freytag SO
Mol Ther; 2000 Mar; 1(3):263-74. PubMed ID: 10933942
[TBL] [Abstract][Full Text] [Related]
13. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial.
Herman JR; Adler HL; Aguilar-Cordova E; Rojas-Martinez A; Woo S; Timme TL; Wheeler TM; Thompson TC; Scardino PT
Hum Gene Ther; 1999 May; 10(7):1239-49. PubMed ID: 10340555
[TBL] [Abstract][Full Text] [Related]
14. In vivo adenovirus-mediated suicide gene therapy of orthotopic bladder cancer.
Sutton MA; Freund CT; Berkman SA; Dang TD; Kattan MW; Wheeler TM; Rowley DR; Lerner SP
Mol Ther; 2000 Sep; 2(3):211-7. PubMed ID: 10985951
[TBL] [Abstract][Full Text] [Related]
15. Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer.
Noguchi M; Yao A; Harada M; Nakashima O; Komohara Y; Yamada S; Itoh K; Matsuoka K
Prostate; 2007 Jun; 67(9):933-42. PubMed ID: 17440952
[TBL] [Abstract][Full Text] [Related]
16. Gene transfer into human prostate adenocarcinoma cells with an adenoviral vector: Hyperthermia enhances a double suicide gene expression, cytotoxicity and radiotoxicity.
Lee YJ; Lee H; Borrelli MJ
Cancer Gene Ther; 2002 Mar; 9(3):267-74. PubMed ID: 11896443
[TBL] [Abstract][Full Text] [Related]
17. Cytopathic effect of in situ gene therapy in prostate cancer.
Ayala G; Wheeler TM; Shalev M; Thompson TC; Miles B; Aguilar-Cordova E; Chakraborty S; Kadmon D
Hum Pathol; 2000 Jul; 31(7):866-70. PubMed ID: 10923926
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: results of a phase I clinical trial.
Sung MW; Yeh HC; Thung SN; Schwartz ME; Mandeli JP; Chen SH; Woo SL
Mol Ther; 2001 Sep; 4(3):182-91. PubMed ID: 11545608
[TBL] [Abstract][Full Text] [Related]
19. Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy.
Nasu Y; Saika T; Ebara S; Kusaka N; Kaku H; Abarzua F; Manabe D; Thompson TC; Kumon H
Mol Ther; 2007 Apr; 15(4):834-40. PubMed ID: 17327829
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy.
DeWeese TL; van der Poel H; Li S; Mikhak B; Drew R; Goemann M; Hamper U; DeJong R; Detorie N; Rodriguez R; Haulk T; DeMarzo AM; Piantadosi S; Yu DC; Chen Y; Henderson DR; Carducci MA; Nelson WG; Simons JW
Cancer Res; 2001 Oct; 61(20):7464-72. PubMed ID: 11606381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
